AJP - GI Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Gastrointest Liver Physiol 290: G328-G334, 2006; doi:10.1152/ajpgi.00367.2005
0193-1857/06 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yang, Y.-Y.
Right arrow Articles by Lee, S.-D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, Y.-Y.
Right arrow Articles by Lee, S.-D.

LIVER AND BILIARY TRACT

Roles of anandamide in the hepatic microcirculation in cirrhotic rats

Ying-Ying Yang,1,2 Han-Chieh Lin,3,4 Yi-Tsau Huang,5 Tzung-Yan Lee,6 Ming-Chih Hou,3,4 Ying-Wen Wang,3,4 Fa-Yauh Lee,2,4 and Shou-Dong Lee3,4

1Institute of Clinical Medicine, National Yang-Ming University School of Medicine, and 2Division of General Medicine and 3Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital; 4Department of Medicine and 5Institute of Traditional Medicine, National Yang-Ming University School of Medicine, and 6Graduate Institute of Traditional Chinese Medicine, Chang Gung University, Taipei, Taiwan

Submitted 8 August 2005 ; accepted in final form 10 October 2005


   ABSTRACT
TOP
 ABSTRACT
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Cannabinoids have been reported to participate in the pathogenesis of peripheral vasodilatation in cirrhosis. However, their roles in increased intrahepatic resistance (IHR) in cirrhotic livers are unknown. We aimed to investigate the effects of cannabinoids in the hepatic microcirculation of cirrhotic rats produced by bile duct ligation. In isolated liver perfusion, portal perfusion pressure (PPP) and the production of eicosanoids in the perfusate were measured. In addition, various hepatic protein levels [cyclooxygenase (COX) isoform and 5-lipoxygenase (5-LOX)] were also determined. Finally, concentration-response curves for PPP and the corresponding production of eicosanoids in response to anandamide (1.44 x 10–10–1.44 x 10–3 M) after indomethacin (COX inhibitor), piriprost (5-LOX inhibitor), or furegrelate (thromboxane A2 synthase inhibitor) preincubation were obtained. The study showed that cirrhotic livers had significantly higher levels of PPP, COX-2 and 5-LOX protein expression, and production of thromboxane B2 (TXB2) and cysteinyl leukotrienes (Cys-LTs) than normal livers. Anandamide induced a dose-dependent increase in PPP in both normal and cirrhotic livers. The anandamide-induced increase in PPP was found concomitantly with a significant increase in TXB2 and Cys-LT production in the perfusate. In response to anandamide administration, cirrhotic livers exhibited a significantly greater increase in IHR and production of TXB2 and Cys-LTs than normal livers. Indomethacin and furegrelate, but not piriprost, significantly ameliorated the anandamide-induced increase in IHR in cirrhotic livers. In conclusion, anandamide plays, in part, an important role in increased IHR of cirrhotic livers. The anandamide-induced increase in IHR in cirrhotic livers may be mediated by increased COX-derived eicosanoid (mainly thromboxane A2) production.

liver perfusion; portal hypertension; eicosanoids; vasoconstriction

INCREASED INTRAHEPATIC RESISTANCE (IHR), an initial event in the development of portal hypertension, is a consequence of the distortion of liver vascular architecture caused by fibrosis, scarring, and nodule formation in cirrhosis (38, 39). Recent studies have demonstrated that there are contractile elements in cirrhotic livers that are able to constrict, in a reversible and graded manner, in response to several agonists, including endothelin 1, norepinephrine, thromboxanes, leukotrienes, etc. (13, 15, 36, 40). This dynamic component had found to be important in increased IHR, and its modulation may become a key therapeutic target in cirrhosis (2).

Cannabinoid receptors (CB1 and CB2) and at least two endocannabinoids, anandamide and 2-arachydonylglycerol, have been identified (5, 24). Anandamide, being the most extensively investigated, was present in peripheral tissues such as the spleen, heart, kidney, gut, cultured endothelial cells, and macrophage cell lines (4, 8, 25, 29). Elevation of circulating levels of anandamide and increase vascular CB1 receptor expression has been reported in cirrhotic humans and animals (1, 9, 37). Acute administration of a CB1 receptor antagonist reduced the elevated mesenteric blood flow and portal pressure, indicating that increased production of anandamide may play a role in splanchnic vasodilatation in CCl4-induced cirrhotic rats (1). The mechanism underlying these vascular effects of anandamide has been proposed to involve in interactions with some vasoactive factors such as eicosanoids (10, 12, 27).

It has been suggested that an increase in the hepatic protein levels of cycloxygenase (COX) and lipoxygenase (LOX) and the production of vasoconstrictive eicosanoids play important roles in the increased IHR in the cirrhotic liver (13, 15). In fact, anandamide has been found to induce COX-2 expression and to release eicosanoids in several cell types (7, 18, 22, 32). However, the potential contribution of anandamide to the increased IHR in the cirrhotic liver has not been investigated. The aims of the present study was to evaluate the possible roles of anandamide in the intrahepatic microcirculation of cirrhotic livers and its interaction with the production of vasoconstrictive eicosanoids.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Animals

Adult male Sprague-Dawley rats (250–350 g) were used in all experiments. Cirrhosis with portal hypertension was produced by common bile duct ligation (CBL) as previously described (21, 44). Sham-operated (sham) rats had their bile ducts exposed but not ligated. All rats were caged at 24°C, with a 12:12-h light-dark cycle, and allowed free access to food and water. Animal studies were approved by the Animal Experiment Committee of the university and conducted according to the Guide for the Care and Use of Laboratory Animals prepared by the National Academy of Science (Washington, DC).

Study Protocol

About 30 days after surgery, three sets of CBL and sham rats were included in the study. All rats were fasted for 18 h before experiments. In this study, COX, 5-LOX, and thromboxane A2 (TXA2) synthase (TXA2S) activities were blocked by indomethacin, piriprost, and furegrelate, respectively.

Experiment 1: Western blot analysis for COX-1, COX-2, and 5-LOX in livers. Liver sections obtained from the first set of animals were used to measure various protein expressions (n = 7 in each group). Liver microsomal fractions were prepared as previously described (44). In brief, part of each liver was sliced off and homogenized in a solution containing 15 mM KCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS, 10 mM EDTA, and 50 mM Tris and protease inhibitors (20 µM pepstatin, 20 µM leupeptin, 1,000 U/ml aprotinin, and 1 mM PMSF) using a Potter-type Teflon glass homogenizer. Cells were solubilized by vigorous vortexing and sonication. The insoluble material in the homogenized solution was pelleted by centrifugation at 10,000 g for 15 min. The supernatant was then centrifuged at 105,000 g for 60 min. A pellet of microsomes was suspended in the homogenized solution and stored at –70°C until used. Protein concentrations were determined by the Bradford method. The purified microsomal protein (60 µg) was loaded into SDS-PAGE gels (4% stacking and 10% resolving gels) and electrophoresed. After fractionation, proteins were electrophoretically transferred to nitrocellulose membranes and probed with primary (rabbit anti-rat COX-1, COX-2, and 5-LOX polyclonal) and secondary antibodies (horseradish peroxidase-conjugated goat anti-rabbit). Subsequent detection of the specific protein bands was visualized by enhanced chemiluminescence (ECL Western Blotting Analysis System, Amersham). Finally, {beta}-actin antibody binding was applied to confirm an equal amount of protein loading. Densitometric quantification of Western blot signal intensity was performed using a desitometric analysis program (Kodak Digital Science KDS 1D 20).


FLOW-CONTROLLED ISOLATED IN SITU LIVER PERFUSION. The perfusion technique has been previously described (11). Under ketamine anesthesia (100 mg/kg), the presence of portal hypertension and cirrhosis was examined. The dilated bile duct was then gently cannulated above the stenosed orifice [using polyethylene (PE)-10 tubing] to monitor bile flow. A ligature was passed around the inferior vena cava (IVC) above the renal veins, and the IVC was injected with 1,400 U heparin/kg body wt. The portal vein was cannulated (PE-100), and the liver was perfused with Krebs solution and pumped with a Miniplus 3 peristaltic pump (Gilson; Middleton, WI) from the reservoir into an overflow chamber via a PALL Ultipor filter (model SQ40S; East Hills, NY), which was oxygenated via a Silastic tubing oxygenator with a mixture of 95% O2-5% CO2 at 37 ± 0.5°C. The abdominal aorta and IVC were cut, allowing exsanguinations of the animals and escape of the perfusate for 10 min to wash out the blood. Thereafter, the thorax was opened, and the right atrium was cannulated (PE-240), advancing the catheter through the IVC up to the outlet of the hepatic vein. When the perfused effluent was clear, the system was closed, and the liver was perfused in a recirculating fashion with a total volume of 100 ml (constant rate: 35 ml/min). A flow probe (T201, Transonic; Ithaca, NY) and two pressure transducers were placed in line, immediately ahead of the portal inlet cannula, to continuously monitor portal flow and perfusion pressure. The results were presented to a PowerLab/4sp-linked computer using Chart version 4.0 for Windows (ADInstruments; Mountain View, CA) with a software data-management program (Microsoft Excel 7.0).


CALCULATIONS. The liver (wet) weight of each animal was weighed in each experiment. IHR was calculated according to the following formula: IHR (in mmHg·ml–1·min–1·g–1) = PPP/Q/liver weight, where PPP is the portal perfusion pressure (in mmHg) corrected for the resistance of the portal vein cannula and Q is the constant flow rate.


VIABILITY AND STABILITY. The global viability of each liver was assessed by the gross appearance of the liver, PPP curve pattern, and bile production (11). Livers were allowed to stabilize for 30 min before drugs were added. Indomethacin (10–5 M), piriprost (27 µM), furegrelate (5 µM), or vehicle was preincubated in the reservoir of the perfusion system 30 min before these experiments.

Experiment 2.1: PPP concentration-response curves to anandamide after preincubation of livers with indomethacin or piriprost. There were four groups (n = 7 in each group) of cirrhotic and normal livers obtained from the second set of CBL and sham rats. Basal PPP in recirculating system was measured for 30 min before the following studies. Concentration-response curves of PPP in response to 1.44 x 10–10–1.44 x 10–3 M anandamide were then performed after preincubation of livers with indomethacin or its vehicle and piriprost or its vehicle.

Experiment 2.2: anandamide-stimulated intrahepatic thromboxane B2, 6-keto-PGF1{alpha}, and cysteinyl leukotriene release in liver perfusates after preincubation with indomethacin or piriprost. Liver perfusates used in this experiment were obtained from the second set of livers (n = 7 in each group) in experiment 2.1. Three milliters of the perfusate were obtained before (0-min time point) and 30 min (30-min time point) after the recirculating system was begun to estimate the basal production of eicosanoids. Thereafter, liver perfusates were obtained again after sequential doses of anandamide administration (70-min time point) to estimate anandamide-stimulated eicosanoid productions. The samples were stored at –80°C. To measure cysteinyl leukotrienes (Cys-LTs), methanol (1.5 ml) was immediately added to the samples. Thromboxane B2 (TXB2), 6-keto-PGF1{alpha}, and Cys-LT productions were quantified in duplicate using a commercially available EIA kit. Cys-LTs represent the sum of leukotriene C4, leukotriene D4, and leukotriene E4. TXB2 and 6-keto-PGF1{alpha} are the end metabolites of TXA2 and PGI2, respectively. The basal production of eicosanoids was expressed in picograms per milliliter per minute per liver weightt. The extent of the anandamide-stimulated eicosanoid production was expressed as absolute changes ({Delta}) in picograms per milliliter per minute per liver weight from the basal level.

Experiment 3: effect of the TXA2S inhibitor furegrelate in PPP concentration-response curves to anandamide and TXB2 production. The third set of CBL and sham rats (n = 7 in each group) was included in this experiment. The pecific TXA2S inhibitor furegrelate [5-(3-pyridinyl-methyl)bensofurancarboxylic acid, 1 mg/100 g body wt (5 µM)] was added in the perfusate to inhibit TXA2 production (46). Thirty minutes later, concentration-response curves for PPP in response to anandamide (1.44 x 10–10–1.44 x 10–3 M) were performed with the preincubation of furegrelate or vehicle (saline). Additionally, anandamide-stimulated TXB2 productions were measured in perfusates to assess the appropriateness of the dosage of furegrelate used to block TXA2S activity.

Chemicals

Anandamide, piriprost, furegrelate, COX isoform, and 5-LOX polyclonal antiboidies and EIA kits for TXB2, 6-keto-PGF1{alpha} and Cys-LTs were purchased from Cayman Chemical (Ann Harbor, MI). Substances other than those described above were purchased from Sigma Chemical. Indomethacin was freshly prepared in a 100 mM sodium carbonate buffer (pH 11.4). Piriprost was freshly prepared in DMSO. Furegrelate was dissociated in saline. Control experiments indicated that all the solvent used in this study had no direct effect on PPP and eicosanoid productions at these concentrations.

Statistical Analysis

Data are given as means ± SE. Statistical significance in each group was tested using one-way ANOVA with individual means detected by the Student-Newman-Keuls test. When criteria for parametric testing were violated, the appropriate nonparametric test (Mann-Whitney U-test) was used. Concentration-response curves of PPP to anandamide were analyzed by repeated-measures ANOVA followed by a post hoc test (Games and Howell variant of the Turkey and t-test) to compare groups at each dose separately. Protein levels between the two groups were compared using Student's t-test. Significance was determined at P < 0.05.


   RESULTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
All cirrhotic rats had portal hypertension, ascites, and splenomegaly by gross inspection. Body weight was not different between CBL (407 ± 13 g) and sham (378 ± 22 g) rats. Liver weight was greater in CBL (29.3 ± 1.2 g, P < 0.01) than sham (18.5 ± 0.9 g) rats.

Experiment 1: Western Blot Analysis for COX-1, COX-2, and 5-LOX in Livers

Hepatic protein levels of COX-2 and 5-LOX were higher in CBL than sham rats (Fig. 1, B and C). However, COX-1 protein expression was not different between normal and cirrhotic livers (Fig. 1A).



View larger version (31K):
[in this window]
[in a new window]
  		Fig. 1. Western blot analysis of protein levels of cyclooxygenase (COX)-1 (A), COX-2 (B), and 5-lipoxygenase (5-LOX; C) in all livers (n = 7 in each group). #P < 0.05 vs. sham (S). CBL, common bile duct-ligated livers.

 
Experiment 2.1: PPP Concentration-Response Curves to Anandamide after Preincubation of Livers with Indomethacin or Piriprost

Overall, basal PPP and calculated IHR [PPP: 19.7 ± 1.8 (CBL) vs. 8.9 ± 0.7 (sham) mmHg, P < 0.01; IHR: 17.8 ± 4.7 (CBL) vs. 4.7 ± 0.7 (sham) mmHg·ml–1·min–1·g liver wet wt–1, P < 0.01] were higher in cirrhotic livers than in normal livers. In addition, baseline PPP in the cirrhotic liver after preincubation with vehicle (20.1 ± 2.0 mmHg) was no different from the cirrhotic liver after preincubation with indomethacin (19.4 ± 1.3 mmHg), piriprost (19.8 ± 1.2 mmHg), or furegrelate (18.7 ± 3.2 mmHg). Similarly, baseline PPP in the normal liver after preincubation with vehicle (9.2 ± 0.5 mmHg) was no different from those after preincubation with indomethacin (8.9 ± 0.8 mmHg), piriprost (8.7 ± 0.5 mmHg), or furegrelate (9.3 ± 0.4 mmHg). In the vehicle-preincubated group, anandamide produced concentration-dependent increases in PPP in all livers. Magnitudes of the increases in PPP were significantly greater in cirrhotic livers than in normal livers with each concentration of anandamide (Fig. 2, A–C). Preincubation with indomethacin significantly attenuated the increased response of cirrhotic livers to anandamide (a rightward shift of the concentration-response curves of PPP, P < 0.05; Fig. 2A). However, preincubation with piriprost, a 5-LOX inhibitor, did not significantly change concentration-response curves of PPP to anandamide in cirrhotic livers (Fig. 2B). In normal livers, concentration-response curves of PPP to anandamide were not affected by preincubation with either indomethacin or piriprost (Fig. 2, A and B).



View larger version (31K):
[in this window]
[in a new window]
  		Fig. 2. Absolute changes ({Delta}) in portal perfusion pressure (PPP) to anandamide (1.44 x 10–10–1.44 x 10–3 M) in livers preincubated with indomethacin (Ind; A), piriprost (Piri; B), and furegrelate (Fur; C). V, vehicle; S, normal livers. #P < 0.01 vs. S-V; *P < 0.05 vs. CBL-V.

 
Experiment 2.2: Anandamide-Stimulated Intrahepatic TXB2, 6-Keto-PGF1{alpha}, and Cys-LT Release in Liver Perfusates after Preincubation with Indomethacin or Piriprost

Basal productions of TXB2, 6-keto-PGF1{alpha}, and Cys-LTs were significantly higher in cirrhotic livers than in normal livers (Fig. 3, A–C). In the vehicle-preincubated group, cumulative doses of anandamide caused a significant increase in the production of TXB2 and Cys-LTs in the perfusate (Fig. 4, A–C). The absolute increases in TXB2 and Cys-LTs were significantly greater in cirrhotic livers than in normal livers (sham vs. CBL: 184 ± 84 vs. 2,469 ± 654 pg·ml–1·min–1·g liver wt–1 for TXB2 and 205 ± 82 vs. 441 ± 91 pg·ml–1·min–1·g liver wt–1 for Cys-LTs, P < 0.01; Fig. 4, A and C). However, anandamide only induced a little increase of 6-keto-PGF1{alpha} in both normal and cirrhotic livers (sham vs. CBL: 12.6 ± 7.5 vs. 14.0 ± 6.1 pg·ml–1·min–1·g liver wt–1; Fig. 4B). Preincubation with indomethacin or piriprost significantly inhibited anandamide-related TXB2 and Cys-LT productions, indicating that the doses used in this study were adequate to block the increased COX and 5-LOX activity in cirrhotic livers (Fig. 4, A and C).



View larger version (11K):
[in this window]
[in a new window]
  		Fig. 3. Production of thromoxane B2 (TXB2; A), 6-keto-PGF1{alpha} (B), and cysteinyl leukotrienes (Cys-LTs; C) in perfusates of cirrhotic and normal livers. #P < 0.01 vs. sham.

 


View larger version (19K):
[in this window]
[in a new window]
  		Fig. 4. Anandamide-stimulated (1.44 x 10–10–1.44 x 10–3 M) absolute increases ({Delta}) in hepatic TXB2 (A), 6-keto-PGF1{alpha} (B), and Cys-LT (C) production. #P < 0.05 vs. S-V; *P < 0.05 vs. CBL-V.

 
Experiment 3: Effect of the TXA2S Inhibitor Furegrelate in PPP Concentration-Response Curves to Anandamide and TXB2 Production

Preincubation with furegrelate significantly ameliorated the anandamide-related increase in PPP in cirrhotic livers (Fig. 2C) as well as the reduction in anandamide-stimulated TXB2 production (Fig. 4A).


   DISCUSSION
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
It has been reported that hepatic protein levels of COX and 5-LOX and the corresponding production of TXA2 and Cys-LTs were increased in cirrhotic livers (13, 15). Meanwhile, increased intrahepatic production of TXA2 and Cys-LTs has been demonstrated to play an important role in increased IHR in cirrhosis (13, 15, 46). In line with these observations, the present study shows that protein levels of COX-2 and 5-LOX and the corresponding production of TXA2 and Cys-LTs were significantly higher in cirrhotic livers than in normal livers (Figs. 1 and 3). However, protein levels of COX-1 and 6-keto-PGF1{alpha} production in the perfusate were similar between normal and cirrhotic livers. Previous studies have demonstrated that, although higher hepatic COX-2 mRNA expression was observed in cirrhotic livers than in normal livers, COX-1 plays a major role in increased IHR in cirrhotic livers and is the main source responsible for the increased hepatic production of TXA2 (13, 14, 46).

It has been suggested that certain actions of the cannabinoids could be explained by the mechanism involving the synthesis of eicosanoids (7, 18, 22, 32). In bovine coronary arteries, cannabinoids induced vasorelaxation by the release of vasodilatory eicosanoids (32). An in vitro study (20) of smooth muscle from the guinea pig distal colon demonstrated a contractile response of cannabinoids after the release of eicosanoids. Eicosanoids are the major products of arachidonic acids, which can be divided into two groups according to their vasodilator or vasoconstrictor effects (38). To our knowledge, the effects of anandamide in increased IHR and intrahepatic eicosanoid productions in cirrhosis have not been established. Our data demonstrated that anandamide induced a significantly greater increase in IHR in cirrhotic livers than in normal livers (Fig. 2). In other words, the cirrhotic livers may exert a hyperresponse to anandamide. It has been shown that the plasma levels of anandamide drawn from a peripheral vein were higher in cirrhotic patients than in healthy subjects (9). Theoretically, the concentration of anandamide in the portal vein should also be increased in cirrhotic patients or animals, although there are no data reporting the concentration of anandamide in portal venous blood. In the present study, using the liver perfusion model, the cumulated increase in anandamide dosage in the perfusate may be similar to the elevated concentration of anandamide in portal venous blood in vivo. Accordingly, the present study suggested that anandamide plays, in part, a role in increased IHR in the cirrhotic liver.

It is of interest to observe the existence of different hemodynamic characteristics in the peripheral and intrahepatic circulation in cirrhosis. The systemic and splanchnic vasculatures exhibit marked vasodilatation, but the intrahepatic microvasculature displays marked vasoconstriction in cirrhosis (3, 43). PGI2, TXA2, and Cys-LTs are metabolites of arachidonic acid, which is released by chemical and mechanical stimuli (28). Under normal physiological conditions, normal vascular tone is maintained by the balance between the activity of vasodilators and vasoconstrictors. In cirrhosis with portal hypertension, peripheral vasodilatation is mainly the result of overproduction of nitric oxide and PGI2, which overcomes vasoconstrictive activity (17, 30, 43). In contrast, dynamic components of increased IHR in the cirrhotic liver are the result of increased production of TXA2 and Cys-LTs, which masks vasodilatory activities (13, 15, 36, 40), Anandamide has been reported to induce both vasodilatation and vasoconstriction in cirrhotic and noncirrhotic humans and animals (1, 4, 9, 20, 37). The present study demonstrates the effect of anandamide to increase IHR in cirrhotic livers. Indeed, anandamide has been found to stimulate COX activity with the subsequent release of prostanoids in mature bovine aorta cell lines and human neuroglioma cells (22, 45). In our study, the increased anandamide-related TXA2 production in cirrhotic livers may be caused by an interaction between anandamide and COX with subsequent releasing of vasoactive eicosanoids. However, the effects of anandamide depend on its concentration as well as the vascular territory being examined (26). Therefore, it is possible that, in cirrhosis with portal hypertension, anandamide acts as a vasodilator in the peripheral circulation, as previously reported (1, 7, 27), whereas it serves as a vasoconstrictor in the hepatic microcirculation, as shown in the present study.

A recent study (6) has reported that dilatation of rabbit cerebral arterioles by anandamide, possibly via the production of vasodilatory prostanoids, is blocked by indomethacin. In this study, preincubation with both indomethacin (a COX inhibitor) and piriprost (a 5-LOX inhibitor) attenuated the anandamide-related increase in IHR in cirrhotic and normal livers. However, the magnitude of changes reached statistical significance only in cirrhotic livers with indomethacin preincubation. In addition, preincubation of indomethacin decreased TXB2 production, whereas 6-keto-PGF1{alpha} production remained unchanged. Moreover, preincubation with furegrelate (a TXA2S inhibitor) caused an attenuation of the anandamide-induced increase in IHR and a decrease in TXB2 production, which is similar to that observed in the cirrhotic liver with indomethacin preincubation. Together, these results indicate that the increase in IHR by anandamide in cirrhotic livers was mainly mediated by the increase in COX activity with subsequent TXA2 production.

A variety of receptor-mediated (CB1 and CB2 receptor) effects of cannabinoids have been reported (18). Anandamide can induce an EDHF-mediated relaxation response, via the vascular CB1 receptor, in isolated rat mesenteric and coronary arteries (33, 35). Several investigations have recently reported that anandamide production can be stimulated during hemorrhagic shock or by the administration of bacterial lipopolysaccharide (41, 42). In addition, the increased anandamide production was mostly from monocytes, because separated monocytes administered to a euvolemic recipient animal caused a marked hypotensive effect (41, 42). Moreover, the hypotensive effect induced by the administration of monocytes from cirrhotic patients or cirrhotic rats to normal rats can be prevented by pretreatment with specific CB1 receptor antagonists (1). Recent studies (16, 19, 23) have demonstrated that CB1 and CB2 receptors are marked upregulated in stellate cells of cirrhotic livers. In contrast, several effects of cannabinoids are not mediated via cannabinoid receptors such as inhibition of L-type Ca2+ channels, stimulation of vanilloid VR1 receptors, transient changes in intracellular Ca2+, and disruption of gap junction function (18). However, data on the effects of cannabinoids in cirrhotic livers are limited, and more studies are needed to elucidate the role of cannabinoids in cirrhotic livers (2, 31, 34).

In summary, this study suggests that anandamide contributes in part to increased IHR in cirrhotic livers. In addition, the anandamide-related increase in IHR in cirrhotic livers may be mediated by increased production of COX-derived eicosanoids (mainly TXA2).


   GRANTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
This study was supported by National Science Council Grant NSC93-2314-B-075-038 and by Taipei Veterans General Hospital (Taipei, Taiwan) Grant VGH93-207.


   FOOTNOTES
 

Address for reprint requests and other correspondence: H.-C. Lin, Div. of Gastroenterology, Dept. of Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Rd., Taipei 11217, Taiwan (e-mail: hclin{at}vghtpe.gov.tw)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Bátkai S, Járai Z, Wagner JA, Gogaraju SK, Varga K, Liu J, Wang L, Mirshahi F, Khanolkar AD, Makriyannis A, Urbaschek NG R Jr, Sanyal AJ, and Kunos G. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 7: 827–832, 2001.[CrossRef][ISI][Medline]
  2. Bosch J, Abraldes JG, and Groszmann RJ. Current management of portal hypertension. J Hepatol 38, Suppl 1: S54–S68, 2003.[Medline]
  3. Colombato LA, Abillos A, and Groszmann RJ. Temporal relationship of peripheral vasodilatation, plasma volume expansion and the hyperdynamic circulatory state in portal-hypertensive rats. Hepatology 15: 323–328, 1991.[ISI]
  4. Deutsch DG, Goligorsky MS, Schmid PC, Krebsbach RJ, Schmid HHO, Das SK, Dey SK, Arreaza G, Thorup C, Stefano G, and Moore LC. Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest 100: 1538–1546, 1997.[ISI][Medline]
  5. Dewey WL. Cannabinoid pharmacology. Pharmacol Rev 38: 151–178, 1986.[Abstract]
  6. Ellis EF, Moore SF, and Willoughby KA. Anandamide and {Delta}9-THC dilation of cerebral arterioles is blocked by indomethacin. Am J Physiol Heart Circ Physiol 269: H1859–H1864, 1995.[Abstract/Free Full Text]
  7. Felder CC, Briley EM, Axelrod J, Simpson JT, Mackie K, and Devane WA. Anandamide, an endogenous cannabimimetic eicosanoid, bands to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci USA 90: 7656–7660, 1993.[Abstract/Free Full Text]
  8. Felder CL, Nielsen A, Briley EM, Palkovit M, Priller J, Axelrod J, Simpson JT, Mackie K, and Devane WA. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett 393: 231–235, 1996.[CrossRef][ISI][Medline]
  9. Fernández-Rodriguez CM, Romero J, Petros TJ, Bradshaw H, Gasalla JM, Gutiérrez ML, Leldó JL, Santander C, Perez-Fernández T, Tomás E, Cacho G, and Walker JM. Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis. Liver Int 24: 477–483, 2004.[CrossRef][ISI][Medline]
  10. Fleming I, Schermer B, Poop R, and Busse R. Inhibition of the production of endothelium-derived hyperpolarizing factor by cannabinoid receptor agonists. Br J Pharmacol 126: 949–960, 1999.[CrossRef][ISI][Medline]
  11. Gores GJ, Kost LJ, and Larusso NF. The isolated perfused rat liver: conceptual and practical considerations. Hepatology 6: 511–517, 1986.[ISI][Medline]
  12. Grainger J and Boachie-Ansah G. Anandamide-induced relaxation of sheep coronary arteries: the role of the vascular endothelium, arachidonic acid metabolites and potassium channels. Br J Pharmacol 134: 1003–1012, 2001.[CrossRef][ISI][Medline]
  13. Graupera M, Garcca-Pagan JC, Abraldes JG, Peralta C, Bragulat M, Corominola H, Bosch J, and Rodés J. Cycloxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers. Hepatology 37: 172–181, 2003.[CrossRef][ISI]
  14. Graupera M, García-Pagán JC, Parés M, Abraldes JG, Roselló J, Bosch J, and Rodés J. Cycloxygenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers. J Hepatol 39: 515–521, 2003.[CrossRef][ISI][Medline]
  15. Graupera M, Garcia-Pagan JC, Titos E, Claria J, Massaguer A, Bosch J, and Rodes J. 5-Lipoxygenase inhibitor reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes. Gasteroenterology 22: 387–393, 2002.[CrossRef]
  16. Grenard P, Julien B, Van Nhieu JT, Li L, Ledent C, Mallat A, and Lotersztajn S. Reduced liver fibrosis in CB1 receptor knockout mice. J Hepatol 40, Suppl 1: 8, 2004.[Medline]
  17. Guarner C, Soriano G, Such J, Teixidó M, Ramis I, Bulbena O, Roselló J, Guarner F, Gelpi E, Balanzó J, and Vilardell F. Systemic prostacyclin in cirrhotic patients. Gastroenterology 102: 303–309, 1992.[ISI][Medline]
  18. Howlett AC and Mukhopadhyay S. Cellular signal transduction by anandamide and 2-arachidonoyglycerol. Chem Phys Lipids 108: 53–70, 2000.[CrossRef][ISI][Medline]
  19. Julien B, Grenard P, Teixeira-Clerc F, Van Nhieu JT, Li L, Karsak M, Zimmer A, Mallat A, and Lotersztajn S. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 128: 742–755, 2005.[CrossRef][ISI]
  20. Kojima S, Sugiura T, Waku K, and Kamikawa Y. Contractile response to a cannabimimetic eicosanoid, 2-arachidonoylglycerol, of longitudinal smooth muscle from the guinea-pig distal colon in vitro. Eur J Pharmacol 444: 203–207, 2002.[CrossRef][ISI][Medline]
  21. Kountouras J, Billing BH, and Scheuer PJ. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol 65: 305–311, 1984.[ISI][Medline]
  22. Kozak KR, Crews BC, Morrow JD, Wang LH, Ma YH, Weinander R, Per-Johan J, and Marnett LJ. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem 277: 44877–44885, 2002.[Abstract/Free Full Text]
  23. Lotersztajn S, Julien B, Teixeira-Clerc F, Grenard P, and Mallat A. Hepatic fibrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol 45: 605–628, 2005.[CrossRef][ISI][Medline]
  24. Matsudo LA, Lolait SJ, Brown MJ, Young AC, and Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561–564, 1999.
  25. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminsky NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, and Vogel Z. Identification of an endogenous 2-monoglyceride, present in cannie gut, that binds to cannabinoid receptors. Biochem Pharmacol 50: 83–90, 1995.[CrossRef][ISI][Medline]
  26. Mechoulam R, Fride E, and Marzo VD. Endocannabinoids. Eur J Pharmacol 359: 1–18, 1998.[CrossRef][ISI][Medline]
  27. Moezi L, Rezayat M, Samini M, Shafaroodi H, Mehr SE, Ebrahimkhani MR, and Dehpou AR. Potentiation of anandamide effects in mesenteric beds isolated from bile duct-ligated rats: role of nitric oxide. Eur J Pharmacol 486: 53–59, 2004.[CrossRef][ISI][Medline]
  28. Morrow JD and Roberts LJ Jr (editors). Goodman & Gilman's the pharmacological basis of therapeutics. In: Lipid-Derived Autacoids. New York: McGraw Hill, 2001, p. 669–685.
  29. Nelson-Garcia JR, Járai Z, Mirshahi F, Kunos G, and Sanyal AJ. Systemic and portal hemodynamic effects of anandamide. Am J Physiol Gastrointest Liver Physiol 280: G14–G20, 2001.[Abstract/Free Full Text]
  30. Oberti F, Sogni P, Cailmail S, Moreau R, Pipy B, and Lebrec D. Role of prostacyclin in hemodynamic alterations in conscious rats with extrahepatic or intrahepatic portal hypertension. Hepatology 18: 621–627, 1993.[CrossRef][ISI]
  31. Petrocellis LD, Cascio MG, and Marzo VD. The endocannabinoid system: a general view and latest additions. Br J Pharmacol 141: 765–774, 2004.[CrossRef][ISI][Medline]
  32. Pratt PF, Hillard CJ, Edgemond WS, and Campbell WB. N-arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor. Am J Physiol Heart Circ Physiol 274: H375–H381, 1998.[Abstract/Free Full Text]
  33. Randall MD and Kendall DA. Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation. Eur J Pharmacol 335: 205–209, 1997.[CrossRef][ISI][Medline]
  34. Randall MD, Kendall DA, and O'Sullivan S. The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol 142: 20–26, 2004.[CrossRef][ISI]
  35. Randall MD, McCulloch AJ, and Kendall DA. Comparative pharmacology of endothelium-derived hyperpolarizing factor and anandamide in rat isolated mesentery. Eur J Pharmacol 333: 191–197, 1997.[CrossRef][ISI][Medline]
  36. Rockey DC. Vascular mediators in the injured liver. Hepatology 37: 4–12, 2003.[CrossRef][ISI][Medline]
  37. Ros J, Clária J, To-Figueras J, Planaguma A, Cejudo-Martín P, Fernández-Varo G, Martin-Ruiz R, Arroyo V, Rivera F, Rodés J, and Jiménez W. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 122: 85–93, 2002.[CrossRef][ISI][Medline]
  38. Sherlock S. Chronic hepatitis and cirrhosis. Hepatology 4, Suppl 1: 25, 1984.[ISI]
  39. Sikuler E, Kravetz D, and Groszmann RJ. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am J Physiol Gastrointest Liver Physiol 248: G618–G625, 1985.[Abstract/Free Full Text]
  40. Tiéche S, De Gottardi A, Kappelar A, Shaw S, Sägesser H, Zimmermann A, and Reichen J. Overexpression of endothelin-1 in bile duct ligated rats: correlation with activation of hepatic stellate cells and portal pressure. J Hepatol 34: 38–45, 2001.[Medline]
  41. Varga K, Wangner JA, Bridgen DT, and Kunos G. Platelet and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 12: 1035–1044, 1998.[Abstract/Free Full Text]
  42. Wagner JA, Varga K, Ellis EF, Rzigalinski BA, Martin BR, and Kunos G. Activation of peripheral CB1 receptor in hemorrhagic shock. Nature 390: 518–521, 1997.[CrossRef][Medline]
  43. Wiest R and Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 35: 478–491, 2002.[CrossRef][ISI][Medline]
  44. Yang YY, Lin HC, Huang YT, Lee TY, Hou MC, Lee FY, Liu RS, Chang FY, and Lee SD. Effect of 1-week losartan administration on bile duct-ligated cirrhotic rats with portal hypertension. J Hepatol 36: 600–606, 2002.[CrossRef][ISI][Medline]
  45. Yazici Z, Folco GC, Drazen JM, Nigam S, and Shimizu T. Advances in prostaglandin, leukotriene, and other bioactive research. In: Induction of COX-2 Expression by the Endocannabinoid Derivative R(+)-methanandamide. New York: Kluwer Academic/Plenum, 2003, p. 145–152.
  46. Yokoyama Y, Xu H, Kresge N, Keller S, Sarmadi AH, Baveja R, Clemens MG, and Zhang JX. Role of thromboxane A2 in early BDL-induced portal hypertension. Am J Physiol Gastrointest Liver Physiol 284: G453–G460, 2003.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
L. Moezi, S. A. Gaskari, and S. S. Lee
Endocannabinoids and Liver Disease. V. Endocannabinoids as mediators of vascular and cardiac abnormalities in cirrhosis
Am J Physiol Gastrointest Liver Physiol, October 1, 2008; 295(4): G649 - G653.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
A A Izzo and M Camilleri
Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects
Gut, August 1, 2008; 57(8): 1140 - 1155.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yang, Y.-Y.
Right arrow Articles by Lee, S.-D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, Y.-Y.
Right arrow Articles by Lee, S.-D.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.